Today

Agents

Chat

Arena

Discover

More

App

Lexaria risks Nasdaq delisting after missing $1 minimum bid price rule - LEXX News | Rallies

Lexaria risks Nasdaq delisting after missing $1 minimum bid price rule

LEXX•2026-08-10

Reverse split and hearing request

A reverse stock split took effect Aug. 3, 2026; shares are trading above $1 under the new CUSIP 52886N604.

A hearing request was filed with the required fee to keep the listing in place while the company seeks to regain compliance.

Nasdaq notice cites minimum bid price noncompliance

Lexaria Bioscience received a Nasdaq notice on Aug. 4, 2026, citing failure to regain compliance with the $1 minimum bid rule.

Nasdaq warned the stock faces delisting, subject to an appeal hearing that would stay any suspension.

Related News

WF International FY26 H1 net loss widens to USD 2.48 million

WXM•2026-08-10

Stellex Capital becomes Team’s largest shareholder, lifts stake to about 35%

TISI•2026-08-10

Neostellar Capital Chairman, CEO Mark D. Klein acquires 26,040 common shares worth $249,984

Sources

S

Lexaria risks Nasdaq delisting after missing $1 minimum bid price rule

Sec

•

2026-08-10

Tenon Medical executes 1-for-35 reverse stock split effective Aug. 10

TNON•2026-08-10

Oramed swings to Q2 FY26 net income of $78.16 million; operating loss widens 11% to $2.77 million

ORMP•2026-08-10